Plasmacytoid dendritic cell and functional HIV Gag p55-specific T cells before treatment interruption can inform set-point plasma HIV viral load after treatment interruption in chronically suppressed HIV-1+ patients

Immunology

Volumn 145, Issue 3, 2015, Pages 380-390

  Papasavvas, Emmanouil ^a   Foulkes, Andrea ^b   Yin, Xiangfan ^a   Joseph, Jocelin ^a   Ross, Brian ^a   Azzoni, Livio ^a   Kostman, Jay R ^c   Mounzer, Karam ^d   Shull, Jane ^d   Montaner, Luis J ^a  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Philadelphia Field Initiating Group for HIV 1 Trials   (United States)

Author keywords

Antiretroviral therapy interruption; HIV specific CD8+ T cells; Plasmacytoid dendritic cells; Set point viral load

Indexed keywords

GAG PROTEIN; GAMMA INTERFERON; PERFORIN; PROTEIN P55; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD3 ANTIGEN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; P55 GAG PRECURSOR PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; PROTEIN PRECURSOR;

ADULT; ARTICLE; CD3+ T LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; CYTOKINE PRODUCTION; DEGRANULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS LOAD; AGED; BLOOD; CD8+ T LYMPHOCYTE; CELL CULTURE; DENDRITIC CELL; DRUG EFFECTS; HIV INFECTIONS; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; ANTI-HIV AGENTS; ANTIGENS, CD3; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DENDRITIC CELLS; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERFERON-GAMMA; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; MIDDLE AGED; PERFORIN; PROTEIN PRECURSORS; RETROSPECTIVE STUDIES; T-LYMPHOCYTES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84931567061     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12452     Document Type: Article

References (57)

1. Altfeld M, Rosenberg ES, Shankarappa R et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 2001; 193:169-80.
2. Malim MH, Emerman M. HIV-1 sequence variation: drift, shift, and attenuation. Cell 2001; 104:469-72.
3. + T cell clones during primary HIV infection. Proc Natl Acad Sci U S A 1997; 94:9848-53.
4. + T cell responses in chronically HIV-1 infected blippers on antiretroviral therapy in relation to viral replication following treatment interruption. J Clin Immunol 2006; 26:40-54.
5. + T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 2002; 8:379-85.
6. + T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 2000; 192:63-75.
7. Chehimi J, Campbell DE, Azzoni L et al. Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J Immunol 2002; 168:4796-801.
8. - plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood 2001; 98:2574-6.
9. Azzoni L, Papasavvas E, Chehimi J, Kostman JR, Mounzer K, Ondercin J, Perussia B, Montaner LJ. Sustained impairment of IFN-γ secretion in suppressed HIV-infected patients despite mature NK cell recovery: evidence for a defective reconstitution of innate immunity. J Immunol 2002; 168:5764-70.
10. Hammer SM, Squires KE, Hughes MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725-33.
11. + T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997; 3:533-40.
12. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-7.
13. Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, Perelson AS, Wolinsky SM. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999; 340:1614-22.
14. Dahl V, Josefsson L, Palmer S. HIV reservoirs, latency, and reactivation: prospects for eradication. Antiviral Res 2010; 85:286-94.
15. + CD4 T cell responses is associated with nonprogression in HIV-1 infection. J Immunol 2002; 169:6376-85.
16. + T memory phenotypes in subtype C HIV-1 infection with viral set point. J Immunol 2009; 182:4751-61.
17. Gloster SE, Newton P, Cornforth D, Lifson JD, Williams I, Shaw GM, Borrow P. Association of strong virus-specific CD4 T cell responses with efficient natural control of primary HIV-1 infection. AIDS 2004; 18:749-55.
18. Klein MR, van Baalen CA, Holwerda AM et al. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995; 181:1365-72.
19. + T cell responses associated with control of viremia. Science 1997; 278:1447-50.
20. Pontesilli O, Carotenuto P, Kerkhof-Garde SR, Roos MT, Keet IP, Coutinho RA, Goudsmit J, Miedema F. Lymphoproliferative response to HIV type 1 p24 in long-term survivors of HIV type 1 infection is predictive of persistent AIDS-free infection. AIDS Res Hum Retroviruses 1999; 15:973-81.
21. Rowland-Jones SL, Dong T, Dorrell L et al. Broadly cross-reactive HIV-specific cytotoxic T-lymphocytes in highly exposed persistently seronegative donors. Immunol Lett 1999; 66:9-14.
22. + T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999; 189:991-8.
23. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68:6103-10.
24. Greenough TC, Brettler DB, Somasundaran M, Panicali DL, Sullivan JL. Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T cell loss: evidence supporting a protective role for CTL in vivo. J Infect Dis 1997; 176:118-25.
25. Rolland M, Heckerman D, Deng W et al. Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. PLoS ONE 2008; 3:e1424.
26. + lymphocytes. Science 1999; 283:857-60.
27. Zuniga R, Lucchetti A, Galvan P et al. Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J Virol 2006; 80:3122-5.
28. Addo MM, Draenert R, Rathod A et al. Fully differentiated HIV-1 specific CD8 + T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection. PLoS ONE 2007; 2:e321.
29. + T cell responses by intracellular cytokine production. Immunol Lett 2001; 79:117-25.
30. + T cells in HIV-infected progressors and long-term nonprogressors. J Immunol 2000; 165:1082-92.
31. + T cells: correlation with viral load. J Virol 2004; 78:3233-43.
32. + patients produce C-C chemokines and inhibit HIV-1 infection. J Immunol 1998; 161:6433-8.
33. Piguet V, Blauvelt A. Essential roles for dendritic cells in the pathogenesis and potential treatment of HIV disease. J Invest Dermatol 2002; 119:365-9.
34. Siegal FP, Spear GT. Innate immunity and HIV. AIDS 2001; 15(Suppl. 5):S127-37.
35. Azzoni L, Papasavvas E, Montaner LJ. Lessons learned from HIV treatment interruption: safety, correlates of immune control, and drug sparing. Curr HIV Res 2003; 1:329-42.
36. Dybul M, Chun TW, Yoder C et al. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci U S A 2001; 98:15161-6.
37. Dybul M, Nies-Kraske E, Daucher M et al. Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters. J Infect Dis 2003; 188:388-96.
38. Fagard C, Oxenius A, Gunthard H et al. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med 2003; 163:1220-6.
39. Papasavvas E, Kostman JR, Mounzer K et al. Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PLoS Med 2004; 1:e64.
40. + count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-96.
41. Papasavvas E, Foulkes A, Li X, Kostman JR, Mounzer KC, Montaner LJ. Evidence of a decrease in CD4 recovery once back on antiretroviral therapy after sequential > or =6 weeks antiretroviral therapy interruptions. J Acquir Immune Defic Syndr 2009; 50:334-5.
42. Pacanowski J, Develioglu L, Kamga I, Sinet M, Desvarieux M, Girard PM, Hosmalin A. Early plasmacytoid dendritic cell changes predict plasma HIV load rebound during primary infection. J Infect Dis 2004; 190:1889-92.
43. Pomerantz RJ, Horn DL. Twenty years of therapy for HIV-1 infection. Nat Med 2003; 9:867-73.
44. Papasavvas E, Kostman JR, Mounzer K et al. Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PLoS Med 2004; 1:1-11.
45. Maecker HT, Dunn HS, Suni MA et al. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods 2001; 255:27-40.
46. Grubbs FE. Sample criteria for testing outlying observations. Ann Math Stat 1950; 21:27-58.
47. + T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002; 3:1061-8.
48. Martins MA, Wilson NA, Reed JS, Ahn CD, Klimentidis YC, Allison DB, Watkins DI. T-cell correlates of vaccine efficacy after a heterologous simian immunodeficiency virus challenge. J Virol 2010; 84:4352-65.
49. Saez-Cirion A, Lacabaratz C, Lambotte O et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A 2007; 104:6776-81.
50. + T-cell responses: relationship to viral load in untreated HIV infection. J Virol 2001; 75:11983-91.
51. + T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol 2002; 76:2298-305.
52. Asmuth DM, Murphy RL, Rosenkranz SL et al. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. J Infect Dis 2010; 201:1686-96.
53. Shirazi Y, Pitha PM. Alpha interferon inhibits early stages of the human immunodeficiency virus type 1 replication cycle. J Virol 1992; 66:1321-8.
54. Portales P, Reynes J, Rouzier-Panis R, Baillat V, Clot J, Corbeau P. Perforin expression in T cells and virological response to PEG-interferon α2b in HIV-1 infection. AIDS 2003; 17:505-11.
55. Tomescu C, Chehimi J, Maino VC, Montaner LJ. NK cell lysis of HIV-1-infected autologous CD4 primary T cells: requirement for IFN-mediated NK activation by plasmacytoid dendritic cells. J Immunol 2007; 179:2097-104.
56. Azzoni L, Foulkes AS, Papasavvas E et al. Pegylated Interferon α2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis 2013; 207:213-22.
57. Tomescu C, Liu Q, Ross BN, Yin X, Lynn K, Mounzer KC, Kostman JR, Montaner LJ. A correlate of HIV-1 control consisting of both innate and adaptive immune parameters best predicts viral load by multivariable analysis in HIV-1 infected viremic controllers and chronically-infected non-controllers. PLoS ONE 2014; 9:e103209.